Turning Point touts positive pivotal NSCLC data, hints at even faster OK — but can it beat Pfizer and Roche?

Turning Point touts positive pivotal NSCLC data, hints at even faster OK — but can it beat Pfizer and Roche?

Source: 
Endpoints
snippet: 

Turning Point Therapeutics has long set a clear goal to shoot for an accelerated approval of repotrectinib, its tyrosine kinase inhibitor for ROS1- or NTRK-driven tumors. Now armed with positive, if preliminary, Phase II data, the biotech said they may be FDA-ready even sooner than expected.